Stonegate Investment Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Stonegate Investment Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$377K	Hold	49,688	–	–	0.01%	289
2025 Q2	$445K	Hold	49,688	–	–	0.01%	255
2025 Q1	$373K	Hold	49,688	–	–	0.01%	254
2024 Q4	$374K	Buy	49,688 +100	+0.2%	+$759	0.01%	246
2024 Q3	$377K	Hold	49,588	–	–	0.01%	264
2024 Q2	$306K	Hold	49,588	–	–	0.01%	265
2024 Q1	$252K	Buy	49,588 +600	+1%	+$3.37K	0.01%	279
2023 Q4	$293K	Hold	48,988	–	–	0.01%	256
2023 Q3	$347K	Hold	48,988	–	–	0.01%	229
2023 Q2	$345K	Hold	48,988	–	–	0.01%	237
2023 Q1	$409K	Hold	48,988	–	–	0.02%	223
2022 Q4	$562K	Hold	48,988	–	–	0.02%	194
2022 Q3	$617K	Hold	48,988	–	–	0.03%	165
2022 Q2	$518K	Hold	48,988	–	–	0.02%	184
2022 Q1	$797K	Hold	48,988	–	–	0.03%	141
2021 Q4	$678K	Buy	+48,988	New	+$648K	0.03%	154

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonegate Investment Group's BCRX Position: Q3 2025 in Review

Stonegate Investment Group held its BioCryst Pharmaceuticals (BCRX) position steady in Q3 2025 at 49,688 shares worth $377K. The position accounts for 0.01% of the portfolio, ranked #289.

Stonegate Investment Group first reported a position in BCRX in Q4 2021 and has held it in 16 quarters since. The position peaked at $797K in Q1 2022. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

Stonegate Investment Group held 49,688 shares of BioCryst Pharmaceuticals worth $377K as of Q3 2025.
Stonegate Investment Group left its BioCryst Pharmaceuticals share count unchanged in Q3 2025.
BioCryst Pharmaceuticals made up 0.01% of Stonegate Investment Group's portfolio in Q3 2025, its #289 holding.
Stonegate Investment Group first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 16 quarters since.
Stonegate Investment Group's BioCryst Pharmaceuticals position peaked at $797K in Q1 2022.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Stonegate Investment Group's 13F filing for Q3 2025, filed 3 Nov 2025.